Niclosamide for children and young adults with difficult leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests niclosamide, a medicine being studied as a new treatment, for pediatric and young adult AML that has come back or did not respond. It mainly focuses on whether the drug can be given safely and what dose might work best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML confirmed by standard testing, and it has relapsed or did not respond after prior treatments
- Your leukemia must still be measurable (for example, enough blasts in bone marrow or blood, or MRD that shows remaining leukemia cells)
- You are between ages 2 and 30, and your body size (BSA) must be 2.10 m² or less
- You must be able to take medicines by mouth or through a tube, and you must have enough organ function on recent blood/urine tests
- You must have recovered from recent cancer treatment (at least 2 weeks or longer depending on prior drug timing)
- You must not have had niclosamide before, and you must meet safety rules for pregnancy prevention (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a lab-made immune-cell treatment (NK cells) for children with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It aims to help the immune system attack leukemia cells in the bone marrow, especially when standard treatments have not worked.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial tests a new drug combination (ziftomenib, venetoclax, and azacitidine) in children and young adults with acute leukemia that has come back or not responded to treatment. It may help if your child's leukemia has certain genetic changes (like KMT2A, NPM1, or NUP98).
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This Phase 1 trial tests ETH-155008, a new medicine, in adults with relapsed or refractory acute myeloid leukemia (AML) or non-Hodgkin lymphoma (NHL). It’s mainly designed to see how the treatment works in the body and whether it may help when standard treatment isn’t available or hasn’t worked.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.